British pharma bigwig AstraZeneca has admitted that its COVID-19 vaccine can lead to a rare blood clotting condition known as Thrombosis with Thrombocytopenia Syndrome (TTS).
The vaccine producer stated in court documents that the inoculation could occasionally induce Thrombosis with Thrombocytopenia Syndrome (TTS), a disorder resulting in blood clots and a reduced platelet count, as reported in The Telegraph.
AstraZeneca, following global outrage over the side effects of the vaccine, said on Tuesday that the benefits of the vaccine “far outweigh” the risks of “extremely rare” potential side effects. - Benefits Of Covishield COVID Vaccine Far Outweigh Extremely Rare Potential Side Effects: AstraZeneca
Coronavirus updates | February 8, 2022 : Rashtra News #Coronavirus #updates #February The country recorded 67,597 new Covid-19 cases on Monday. The total number of infections has reached 4.22 crore, and the active cases have crossed the 11.1 lakh mark.Read | Benefits of COVID vaccine outweigh risks, say expertsYou can track coronavirus cases, deaths and
Coronavirus live | Night curfew in Delhi from Monday over rising Covid cases : Rashtra News #Coronavirus #live #Night #curfew #Delhi #Monday #rising #Covid #cases Healthcare and frontline workers and citizens above 60 years of age with comorbidities would be administered the third dose of the same vaccine they had been given before.More, and for